Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic ...

Measuring cellular poly ADP-ribosylation can unlock new anticancer strategies and approaches. ADP-ribosylation, the attachment of ADP-ribose to proteins, is a common eukaryotic post-translational ...

Her team recently developed a small nanocarrier that actively delivers a poly (ADP-ribose) polymerase (PARP) inhibitor and a demethyltransferase 1 (DNMT1) inhibitor to tumors in mouse cancer models. 1 ...

BRCA1 and BRCA2 genes play a crucial role in repairing damaged DNA. Mutations in BRCA1 and BRCA2 substantially increase the likelihood of breast and ovarian cancer, respectively. This new research ...

Ovarian cancer has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard in the maintenance setting ...

These drugs stop a protein known as poly-ADP ribose polymerase (PARP) from repairing cancer cells, so the cells die. They're given to women who have a mutation in the BRCA gene and HER2-negative ...

Pfizer Ltd has announced that the Scottish Medicines Consortium (SMC) has accepted Talzenna (talazoparib) in combination with ...

Ovarian cancer has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard in the maintenance setting ...

Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) announced that its board has authorized a share repurchase plan on Monday, March 3rd, RTT News reports. The company plans to buyback $5.00 million ...